Ambit Biosciences Announces Establishment Of Clinical Oncology Advisory Board

SAN DIEGO--(BUSINESS WIRE)--Ambit Biosciences today announced the establishment of a Clinical Oncology Advisory Board that will counsel the company in its oncology kinase inhibitor drug discovery and development efforts. Ambit has appointed Brian J. Druker, M.D., and Gordon B. Mills, M.D., Ph.D., as the first members of the Board. Dr. Druker, of the Oregon Health and Science University (OHSU), was instrumental in the development of the blockbuster kinase inhibitor, Gleevec®, which is approved for the treatment of chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST). Dr. Mills, of The University of Texas M. D. Anderson Cancer Center, is best known for his work in identifying kinases and biomarkers used in both the diagnosis and treatment of cancer.
MORE ON THIS TOPIC